About this FactMed analysis covering adverse side effect reports of ACEBROFYLLINE patients who developed DEPRESSION.

FactMed provides MD-approved analysis to help both patients, researchers, and physicians accurately assess the risk profile for more than 20,000 different pharmaceutical products. The below report offers compiled information from Food & Drug Administration and FactMed user submissions. Between January 2004 and October 2012, 3 individuals taking ACEBROFYLLINE reported DEPRESSION to the FDA. A total of 11 ACEBROFYLLINE drug adverse event reaction reports were made with the FDA during this time period. Often the FDA only receives reports of the most critical and severe cases; these numbers may therefore underrepresent the complication rate of the medication.

FDA Research Report

Introduction This page is designed to help you determine the relationship, if any, between ACEBROFYLLINE and DEPRESSION. In doing so, we compare ACEBROFYLLINE with other drugs that cause DEPRESSION, to help you evaluate whether or not ACEBROFYLLINE causes DEPRESSION. Likewise, this page shows the most highly-reported side effects of ACEBROFYLLINE, so you can see if DEPRESSION ranks among ACEBROFYLLINE's most well-known side effects.
Summary Statistics
Reports of ACEBROFYLLINE causing DEPRESSION: 3
Reports of any side effect of ACEBROFYLLINE : 11
Percentage of ACEBROFYLLINE patients where DEPRESSION is a reported side effect: 27.2727%

FDA reports of any drug causing DEPRESSION : 98155
Average percentage for all medicated patients where DEPRESSION is reported as a complication: 0.6152%

Physician opinion on ACEBROFYLLINE as adverse event culprit:

Overall opinion for all reports of this drug:
Most frequent diagnoses/indications for prescribing ACEBROFYLLINE:
PRODUCTIVE COUGH ( 3 patients )
BRONCHIECTASIS ( 3 patients )
( 0 patients )
Drugs with high FDA adverse event association with DEPRESSION:

FOSAMAX (14302 patients)
VIOXX (14004 patients)
CHANTIX (12075 patients)
ACCUTANE (11815 patients)
SEROQUEL (6501 patients)
ASPIRIN (5780 patients)
ZOLOFT (4557 patients)
XANAX (4245 patients)
NEURONTIN (4113 patients)
AVONEX (3912 patients)
TRASYLOL (3803 patients)
LIPITOR (3699 patients)
PAXIL (3588 patients)
CYMBALTA (3414 patients)
LEXAPRO (3199 patients)
NEXIUM (3185 patients)
ZOMETA (3151 patients)
OXYCONTIN (3045 patients)
SYNTHROID (3026 patients)
AMBIEN (3003 patients)
CELEBREX (2979 patients)
LASIX (2957 patients)
PREDNISONE (2859 patients)
TYSABRI (2704 patients)
LISINOPRIL (2635 patients)
PROZAC (2565 patients)
PRILOSEC (2563 patients)
LYRICA (2563 patients)
EFFEXOR (2438 patients)
WELLBUTRIN (2274 patients)
KLONOPIN (2272 patients)
IBUPROFEN (2167 patients)
PREMARIN (2148 patients)
ALBUTEROL (2143 patients)
SINGULAIR (2115 patients)
LEVAQUIN (2109 patients)
YAZ (2093 patients)
ZOCOR (2068 patients)
VICODIN (2055 patients)
LORAZEPAM (2049 patients)
ATIVAN (2036 patients)
CLONAZEPAM (2016 patients)
ATENOLOL (1992 patients)
COUMADIN (1974 patients)
PREVACID (1962 patients)
AREDIA (1960 patients)
CELEXA (1928 patients)
DURAGESIC-100 (1892 patients)
HYDROCHLOROTHIAZIDE (1877 patients)
PROTONIX (1872 patients)
YASMIN (1852 patients)
EFFEXOR XR (1800 patients)
SIMVASTATIN (1794 patients)
PLAVIX (1748 patients)
REBIF (1642 patients)
NORVASC (1635 patients)
ZYPREXA (1609 patients)
ALPRAZOLAM (1604 patients)
PERCOCET (1603 patients)
FUROSEMIDE (1579 patients)
OMEPRAZOLE (1571 patients)
TOPROL-XL (1565 patients)
LEVOTHYROXINE SODIUM (1563 patients)
FOLIC ACID (1539 patients)
VALIUM (1499 patients)
GABAPENTIN (1470 patients)
ACETAMINOPHEN (1445 patients)
TRAZODONE HCL (1438 patients)
PEGASYS (1419 patients)
RIBAVIRIN (1380 patients)
DIAZEPAM (1376 patients)
LAMICTAL (1334 patients)
FLEXERIL (1330 patients)
HEPARIN (1320 patients)
LORTAB (1304 patients)
HUMIRA (1277 patients)
RISPERDAL (1273 patients)
[THERAPY UNSPECIFIED] (1263 patients)
ADVAIR DISKUS 100/50 (1245 patients)
BEXTRA (1243 patients)
NITROGLYCERIN (1239 patients)
METHOTREXATE (1232 patients)
TOPAMAX (1225 patients)
REMICADE (1213 patients)
FOSAMAX PLUS D (1173 patients)
DIGOXIN (1173 patients)
INSULIN (1167 patients)
POTASSIUM CHLORIDE (1150 patients)
VITAMIN D (1133 patients)
OXYCODONE HCL (1118 patients)
ZYRTEC (1117 patients)
PAROXETINE HCL (1087 patients)
CITALOPRAM HYDROBROMIDE (1085 patients)
AMOXICILLIN (1084 patients)
ALENDRONATE SODIUM (1066 patients)
ENBREL (1061 patients)
CRESTOR (1041 patients)
MIRAPEX (1026 patients)
DIOVAN (1020 patients)
MIRENA (1012 patients)
FENTANYL (1011 patients)
DEPAKOTE (1009 patients)
METFORMIN HCL (1000 patients)
AVANDIA (993 patients)
PEG-INTRON (991 patients)
ELAVIL (989 patients)
ALLEGRA (982 patients)
ZANTAC (981 patients)
FLUOXETINE (965 patients)
CALCIUM (957 patients)
TYLENOL (CAPLET) (930 patients)
MULTI-VITAMINS (922 patients)
ABILIFY (920 patients)
HYDROCODONE (919 patients)
MORPHINE (912 patients)
SEROQUEL XR (911 patients)
METOCLOPRAMIDE (909 patients)
PRISTIQ (900 patients)
BETASERON (896 patients)
GLUCOPHAGE (894 patients)
DEXAMETHASONE (893 patients)
ZITHROMAX (888 patients)
METOPROLOL TARTRATE (881 patients)
BACLOFEN (868 patients)
LOPRESSOR (863 patients)
MIRTAZAPINE (858 patients)
REGLAN (856 patients)
TYLENOL (855 patients)
HYDROCODONE BITARTRATE (855 patients)
CALCIUM (UNSPECIFIED) (854 patients)
ACTONEL (851 patients)
CLARITIN (840 patients)
ZOFRAN (835 patients)
ULTRAM (829 patients)
AMITRIPTYLINE HCL (824 patients)
PREMPRO (820 patients)
REMERON (815 patients)
LANTUS (814 patients)
CHAMPIX (810 patients)
FORTEO (807 patients)
PREDNISONE TAB (807 patients)
GEODON (804 patients)
VITAMIN E (803 patients)
ALLOPURINOL (801 patients)
NUVARING (800 patients)
COREG (797 patients)
TRAMADOL HCL (792 patients)
NAPROXEN (791 patients)
MOTRIN (761 patients)
SOMA (760 patients)
COPEGUS (754 patients)
BONIVA (740 patients)
BENADRYL (736 patients)
CIPROFLOXACIN (733 patients)
RANITIDINE (725 patients)
PEPCID (717 patients)
FLONASE (715 patients)
VITAMINS (UNSPECIFIED) (711 patients)
COZAAR (709 patients)
ACETYLSALICYLIC ACID SRT (707 patients)
TEGRETOL (704 patients)
PROMETHAZINE (702 patients)
SUBOXONE (702 patients)
METOPROLOL (702 patients)
CEPHALEXIN (699 patients)
CLONIDINE (699 patients)
ARIMIDEX (699 patients)
KEPPRA (697 patients)
TEMAZEPAM (697 patients)
ASCORBIC ACID (693 patients)
LITHIUM CARBONATE (689 patients)
ZETIA (688 patients)
SERTRALINE HYDROCHLORIDE (674 patients)
HEPARIN SODIUM INJECTION (668 patients)
MULTI-VITAMIN (667 patients)
OXYCODONE (652 patients)
DECADRON (651 patients)
RITALIN (649 patients)
WELLBUTRIN XL (648 patients)
VANCOMYCIN (647 patients)
TAMOXIFEN CITRATE (645 patients)
WARFARIN SODIUM (631 patients)
VITAMIN B-12 (627 patients)
SPIRONOLACTONE (627 patients)
COMPAZINE (624 patients)
LOVENOX (613 patients)
CLINDAMYCIN (604 patients)
SPIRIVA (603 patients)
ALTACE (602 patients)
METFORMIN (600 patients)
AMNESTEEM (599 patients)
FEMARA (594 patients)
DILAUDID (592 patients)
RESTORIL (591 patients)
COLACE (587 patients)
BUPROPION HCL (586 patients)
VERSED (582 patients)
ACTOS (581 patients)
TRILEPTAL (576 patients)
LEVOXYL (571 patients)
KEFLEX (568 patients)
VIAGRA (564 patients)
GLYBURIDE (561 patients)
ZESTRIL (558 patients)
REBETOL (557 patients)
PROVIGIL (556 patients)
MAGNEVIST (555 patients)
PROTAMINE SULFATE (552 patients)
DROSPIRENONE AND ETHINYL ESTRADIOL (551 patients)
ACIPHEX (550 patients)

In addition to reviewing our up-to-date FDA research, users may interact with the FactMed community - currently one million members and growing! FactMed online research and discussions are read by patients, scientists, physicians, and other interested health care parties. Post follow up Questions to learn from our diverse readership. Likewise, patients who have experienced unwanted effects are encouraged to share their Concerns to help educate and inform our members.


Recent FactMed Activity for ACEBROFYLLINE


Issue Description / Topic Timestamp

My Patient Resources

Get your questions answered! Over one million patients, researchers, and health care providers have visited FactMed. If you have a question about DEPRESSION and ACEBROFYLLINE, post it here. You may receive a response from a fellow patient - or a leading expert in the field.
Your Question:

Share your experience: Over one million patients, researchers, and health care providers have visited FactMed. If you have a noteworthy experience as a patient taking ACEBROFYLLINE, post it here. Your story could help a fellow patient - or provide insight to a leading expert in the field.
Your Experience or Concern:

Telemedicine Expert Consults FactMed newest feature allows patients to consult - via realtime videoconferencing - experts in ACEBROFYLLINE. This premium feature connects patients to experts, regardless of geography. FactMed experts charge reasonable rates that may be reimbursable by your insurance as a second-opinion.
We are currently accepting registration for ACEBROFYLLINE experts. If you are a healthcare provider experienced in prescribing ACEBROFYLLINE, please register here.

Your online appointment book for Atlanta Rentals & Services



© 2014 FactMed, Inc
Privacy Policy
Terms of Use